Fintech PR

H World Attends Hotel Investment Conference Asia Pacific 2023

Published

6 months ago

October 31, 2023

h-world-attends-hotel-investment-conference-asia-pacific-2023

Rapid Business Recovery for the Group with Limited-service Hotels Meeting Rigid Market Demand

SINGAPORE and SHANGHAI, Oct. 31, 2023 /PRNewswire/ — From October 23^rd to 25^th, the Hotel Investment Conference Asia Pacific (“HICAP”) 2023 was successfully held in Singapore. This conference focused on the dynamics and future prospects of the hospitality and travel industry in the Asia-Pacific region, discussing topics related to emerging travel trends, new developments in the hotel industry, and economic investment opportunities. It provided insights into the latest market trends and anticipated future directions for the industry. The conference was attended by nearly a thousand industry professionals and esteemed industry leaders. Ms He Jihong, the Chief Financial Officer of H World Group Limited (“H World” or “the Group“), and Mr Murphy Zhu, President of Asia Pacific, were invited to attend the conference and delivered speeches on the Group’s business and the development of the travel industry.

He Jihong highlighted that from the opening of the first Hanting Hotel 18 years ago, H World has become one of the fastest-growing hotel groups in the world and is currently ranked 6^th in the world. H World has rapidly recovered from the impact of the Covid-19. Particularly during Chinese New Year this year, the RevPAR of Legacy-Huazhu (refers to H World’s business in China) rebounded to 140% of the 2019 level. In Q3 2023, Legacy-Huazhu’s RevPAR recovered to 129% of the 2019 level. Speaking about the Chinese economy and the tourism industry, He Jihong emphasized a new consumer trend where individuals of all age groups prioritize “experiential consumption”, which allows them to seek happiness through relatively small budget. H World’s portfolio consisting of over 90% limited-service hotels, is well-suited to meet these consumer needs. In addition, the anticipated rebound of business travel in China further contributes to the favorable outlook for H World’s business.

Regarding customer loyalty programs, He Jihong stated that H World has consistently embraced technological innovation. With their in-house operational system and analytical tools, the Group has significantly enhanced its ability to attract and retain loyalty members. Currently, more than 80% of their bookings come from their proprietary platform, with over 70% of them being made by loyalty members. The Group has a membership base of over 200 million and the number is expected to increase further next year as they work on building a robust ecosystem.

Furthermore, He Jihong emphasized that H World’s management and franchise model played a crucial role in the Group’s rapid growth. By providing a complete supply chain and assigning on-site hotel managers to manage franchised hotels, H World ensures consistent brand quality and revenue while simplifying operations for franchisees, realizing the Group’s rapid expansion to form a network effect, which is expected to open more than 1,000 hotels in the coming year.

During the “A Spotlight on East Asia – Opportunities and Challenges” session, Murphy Zhu also shared the recovery status of H World Group. The domestic consumption in the service industry increased by 21% compared to last year during the October Golden Week period, with tourism, lodging and restaurant businesses being the key drivers. As of September 30, 2023, H World operated 9,157 hotels with 885,756 rooms in operation in 18 countries. For Legacy-Huazhu, the like-for-like comparison with the mature hotel (6,500 hotels) RevPAR saw an increase of 41% compared to last year in Q3 2023, while the blended occupancy rate reached 86%. DH continued its promising business recovery trend and its RevPAR recovered to 107% of the 2019 level. In Q3 2023, H World has a pipeline of 2,970 projects. These solid pipeline results endorse the Group’s growth trends in 2024. Additionally, CJA, a subsidiary of H World, operates more than 200 apartments with 30,000 units in China, creating a strong synergy between hotels and apartments with their extensive network of over 9,000 hotels. In the future, with the accelerated urbanization in China and rapid development of extended-stay segment, H world will be able to create added value for owners and investors.

Photo – https://mma.prnewswire.com/media/2261839/JI_Hotel_Singapore.jpg

View original content:https://www.prnewswire.co.uk/news-releases/h-world-attends-hotel-investment-conference-asia-pacific-2023-301972441.html

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024

Published

4 weeks ago

April 5, 2024

CISION (PR Newswire)

STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826

The following files are available for download:

https://mb.cision.com/Main/87/3956826/2712771.pdf	Invitation to presentation of EQT AB’s Q1 Announcement 2024
https://news.cision.com/eqt/i/eqt-ab-group,c3285895	EQT AB Group

View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs

Published

4 weeks ago

April 5, 2024

CISION (PR Newswire)

kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs

Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Published

4 weeks ago

April 5, 2024

CISION (PR Newswire)

VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html